CH Biotech R&D Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

CH Biotech R&D 4.43% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

4.4%

Temettü verimi

-0.0009%

Geri Alım Getirisi

Toplam Hissedar Getirisi	4.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	18.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	NT$3.590
Ödeme oranı	109%

Son temettü ve geri alım güncellemeleri

Recent updates

CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

Apr 05

A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

Mar 18

Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Feb 09

Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

Jan 11

Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Dec 15

Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

Nov 24

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 6534 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: 6534 şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 9 yıldır temettü ödemiştir.

Piyasaya Karşı Temettü Getirisi

CH Biotech R&D Piyasaya Karşı Temettü Getirisi

6534 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (6534)	4.4%
Pazarın Alt %25'i (TW)	1.7%
Pazarın En İyi %25'i (TW)	4.4%
Sektör Ortalaması (Chemicals)	2.6%
Analist tahmini (6534) (3 yıla kadar)	n/a

Önemli Temettü: 6534 'in temettüsü ( 4.43% ), TW piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.69% ) daha yüksektir.

Yüksek Temettü: 6534 'in temettüsü ( 4.43% ) TW pazarındaki temettü ödeyenlerin en üst %25'indedir ( 4.41% )

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 109% ) nedeniyle 6534 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 6534 temettü ödüyor ancak şirketin serbest nakit akışı yok.

CH Biotech R&D Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 2/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of NT$0.50 per share

Upcoming dividend of NT$3.09 per share

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the Second Half of 2023, Payable on April 12, 2024

Upcoming dividend of NT$1.00 per share at 2.6% yield

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023

Upcoming dividend of NT$3.88 per share at 4.7% yield

Recent updates

Third quarter 2024 earnings released: NT$0.89 loss per share (vs NT$0.45 loss in 3Q 2023)

CH Biotech R&D Co., Ltd. to Report Q3, 2024 Results on Nov 05, 2024

Upcoming dividend of NT$0.50 per share

Second quarter 2024 earnings released: EPS: NT$1.27 (vs NT$1.96 in 2Q 2023)

CH Biotech R&D Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Now 20% overvalued

First quarter 2024 earnings released: EPS: NT$4.08 (vs NT$4.05 in 1Q 2023)

CH Biotech R&D Co., Ltd. to Report Q1, 2024 Results on May 07, 2024

Upcoming dividend of NT$3.09 per share

Full year 2023 earnings released: EPS: NT$4.76 (vs NT$4.79 in FY 2022)

Dividend of NT$3.09 announced

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the Second Half of 2023, Payable on April 12, 2024

CH Biotech R&D Co., Ltd., Annual General Meeting, May 21, 2024

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: NT$0.45 loss per share (vs NT$0.30 loss in 3Q 2022)

New minor risk - Shareholder dilution

Upcoming dividend of NT$1.00 per share at 2.6% yield

Second quarter 2023 earnings released: EPS: NT$1.96 (vs NT$3.44 in 2Q 2022)

CH Biotech R&D Co., Ltd. Approves Cash Dividend for the First Half Ended June 30, 2023

Full year 2022 earnings released: EPS: NT$4.79 (vs NT$3.00 in FY 2021)

Upcoming dividend of NT$3.88 per share at 4.7% yield

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: NT$6.22 (vs NT$2.56 in 1H 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of NT$1.50 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

CH Biotech R&D Co., Ltd., Annual General Meeting, Jun 08, 2022

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS NT$2.94 (vs NT$2.12 in 1H 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$0.50 per share

Investor sentiment improved over the past week

CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt

Full year 2020 earnings released: EPS NT$1.19 (vs NT$2.26 in FY 2019)

A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns

CH Biotech R&D Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day low: NT$50.00

Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture

New 90-day low: NT$52.10

Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?

Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield

New 90-day high - NT$69.30

First half earnings released

Upcoming Dividend of NT$1.10 Per Share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin